Another humanized anti–LAG-3 monoclonal antibody (Favezelimab/MK-4280), in combination with pembrolizumab (Keytruda) is currently in clinical trials for treatment of melanoma, NSCLC, CRC and RCC (trial numbers: NCT04305054, NCT04303169, NCT04938817, NCT03516981, NCT05600309, NCT05064059, NCT04895722, NCT04626518, NCT04626479). Here, LAG3 is linked to renal cell carcinoma.